NASDAQ: JANXJanux Therapeutics Inc Stock
$48.88+0.19 (+0.39%)
Updated Apr 22, 2024
JANX Price
$48.88
Fair Value Price
-$0.94
Market Cap
$2.53B
52 Week Low
$5.65
52 Week High
$58.69
P/E
-37.03x
P/B
7.33x
P/S
58.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.08M
Earnings
-$58.29M
Gross Margin
100%
Operating Margin
-721.18%
Profit Margin
-721.2%
Debt to Equity
0.11
Operating Cash Flow
-$51M
Beta
1.67
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
JANX Overview
Janux Therapeutics Incorporated is a biopharma developing therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients with cancer. Its lead TRACTr product candidates target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company's EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. Janux Therapeutics was incorporated in 2017 and is headquartered in La Jolla, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how JANX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JANX ($48.88) is overvalued by 5,272.91% relative to our estimate of its Fair Value price of -$0.94 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
JANX ($48.88) is not significantly undervalued (5,272.91%) relative to our estimate of its Fair Value price of -$0.94 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
JANX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more JANX due diligence checks available for Premium users.
Be the first to know about important JANX news, forecast changes, insider trades & much more!
JANX News
Valuation
JANX fair value
Fair Value of JANX stock based on Discounted Cash Flow (DCF)
Price
$48.88
Fair Value
-$0.94
Undervalued by
5,272.91%
JANX ($48.88) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
JANX ($48.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
JANX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
JANX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-37.03x
Industry
16.21x
Market
41x
JANX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.33x
Industry
5.82x
JANX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
JANX's financial health
Profit margin
Revenue
$2.5M
Net Income
-$11.8M
Profit Margin
-477.8%
JANX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
JANX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$380.4M
Liabilities
$36.1M
Debt to equity
0.11
JANX's short-term assets ($349.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JANX's short-term assets ($349.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JANX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.9M
Investing
$11.1M
Financing
$831.0k
JANX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
JANX vs Biotech Stocks
Janux Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.